Want to join the conversation?
$GILD 2Q15 Call: Non-GAAP R&D expenses were $702MM, up 30% YoverY due to continued progression and expansion of clinical studies, particularly Phase 3 studies in liver disease and oncology areas. Non-GAAP SG&A expenses were up 34% YoverY to $761MM. Ended 2Q15 with $14.7Bil in cash and investments, and generated cash flow from operations of $5.7Bil.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.